Ishizuka Seiichi, Kurihara Noriyoshi, Hiruma Yuko, Miura Daishiro, Namekawa Jun-ichi, Tamura Azusa, Kato-Nakamura Yuko, Nakano Yusuke, Takenouchi Kazuya, Hashimoto Yuichi, Nagasawa Kazuo, Roodman G David
Teijin Institute for Bio-Medical Research, Hino, Tokyo, Japan.
J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):269-77. doi: 10.1016/j.jsbmb.2007.11.007. Epub 2008 Apr 22.
(23S,25S)-N-Benzyl-1alpha,25-dihydroxyvitamin D(3)-26,23-lactam ((23S,25S)-N-benzyl-1alpha,25-(OH)(2)D(3)-26,23-lactam, (23S,25S)-DLAM-1P) antagonizes nuclear vitamin D receptor (VDR)-mediated differentiation of human promyelocytic leukemia (HL-60) cells [Y. Kato, Y. Nakano, H. Sano, A. Tanatani, H. Kobayashi, R. Shimazawa, H. Koshino, Y. Hashimoto, K. Nagasawa, Synthesis of 1alpha,25-dihydroxy vitamin D(3)-26,23-lactams (DLAMs), a novel series of 1alpha,25-dihydroxy vitamin D(3) antagonist, Bioorg. Med. Chem. Lett. 14 (2004) 2579-2583]. To enhance its VDR antagonistic actions, we synthesized multiple analogues of 1alpha,25-(OH)(2)D(3)-26,23-lactam. Among these analogues, (23S,25S)-N-phenetyl-1alpha,25-(OH)(2)D(3)-26,23-lactam, ((23S,25S)-DLAM-2P) had the strongest VDR binding affinity, which was 3 times higher than that of (23S,25S)-DLAM-1P. The 1alpha,25-(OH)(2)D(3)-26,23-lactam analogues never induced HL-60 cell differentiation even at 10(-6)M, but (23S,25S)-DLAM-1P and (23S,25S)-DLAM-2P significantly and dose-dependently inhibited HL-60 differentiation induced by 10(-8)M 1alpha,25-dihydroxyvitamin D(3) (1alpha,25-(OH)(2)D(3)). These compounds also inhibited human and mouse cultures of osteoclast formation by marrow cells treated with 1alpha,25-(OH)(2)D(3). Moreover, the 1alpha,25-(OH)(2)D(3)-26,23-lactam analogues minimally induced 25-hydroxyvitamin D(3)-24-hydroxylase gene expression in HL-60 cells and human and mouse osteoblastic cells, but 10(-6)M (23S,25S)-DLAM-1P or (23S,25S)-DLAM-2P significantly blocked 24-hydroxylase gene expression induced by 10(-8)M 1alpha,25-(OH)(2)D(3). (23S,25S)-DLAM-2P was 5-12 times more potent as a vitamin D antagonist than (23S,25S)-DLAM-1P in HL-60 cells, human and mouse bone marrow cultures. These results demonstrate that (23S,25S)-DLAM-1P and (23S,25S)-DLAM-2P antagonize HL-60 cell differentiation and osteoclast formation by human and mouse osteoclast precursors induced by 1alpha,25-(OH)(2)D(3) through blocking VDR-mediated gene transcription. In contrast, (23S)-25-deoxy-1alpha-hydroxyvitamin D(3)-26,23-lactone, which only blocks human VDR, these vitamin D antagonists can block VDR in human cells and rodent cells.
(23S,25S)-N-苄基-1α,25-二羟基维生素D(3)-26,23-内酰胺((23S,25S)-N-苄基-1α,25-(OH)(2)D(3)-26,23-内酰胺,(23S,25S)-DLAM-1P)可拮抗核维生素D受体(VDR)介导的人早幼粒细胞白血病(HL-60)细胞分化[Y. 加藤,Y. 中野,H. 佐野,A. 塔纳塔尼,H. 小林,R. 岛泽,H. 小筱,Y. 桥本,K. 长泽,新型1α,25-二羟基维生素D(3)拮抗剂1α,25-二羟基维生素D(3)-26,23-内酰胺(DLAMs)的合成,生物有机与药物化学快报14 (2004) 2579 - 2583]。为增强其VDR拮抗作用,我们合成了1α,25-(OH)(2)D(3)-26,23-内酰胺的多种类似物。在这些类似物中,(23S,25S)-N-苯乙基-1α,25-(OH)(2)D(3)-26,23-内酰胺((23S,25S)-DLAM-2P)具有最强的VDR结合亲和力,比(23S,25S)-DLAM-1P高3倍。1α,25-(OH)(2)D(3)-26,23-内酰胺类似物即使在10(-6)M时也从未诱导HL-60细胞分化,但(23S,25S)-DLAM-1P和(23S,25S)-DLAM-2P显著且剂量依赖性地抑制10(-8)M 1α,25-二羟基维生素D(3)(1α,25-(OH)(2)D(3))诱导的HL-60分化。这些化合物还抑制了用1α,25-(OH)((2)D(3)处理的骨髓细胞形成人及小鼠破骨细胞。此外,1α,25-(OH)(2)D(3)-26,23-内酰胺类似物在HL-60细胞以及人和小鼠成骨细胞中极少诱导2-5-羟基维生素D(3)-24-羟化酶基因表达,但10(-6)M (23S,25S)-DLAM-1P或(23S,25S)-DLAM-2P显著阻断10(-8)M 1α,(25)-(OH)(2)D(3)诱导的24-羟化酶基因表达。在HL-60细胞、人和小鼠骨髓培养物中,(23S,25S)-DLAM-2P作为维生素D拮抗剂的效力比(23S,25S)-DLAM-1P高5 - 12倍。这些结果表明,(23S,25S)-DLAM-1P和(23S,25S)-DLAM-2P通过阻断VDR介导的基因转录,拮抗1α,25-(OH)((2)D(3)诱导的HL-60细胞分化以及人和小鼠破骨细胞前体形成破骨细胞。相比之下,仅阻断人VDR的(23S)-25-脱氧-1α-羟基维生素D(3)-26,23-内酯,这些维生素D拮抗剂可阻断人细胞和啮齿动物细胞中的VDR。